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Abstract
Background: Scarce data exist concerning the long-term effect of percutaneous transluminal
renal angioplasty (PTRA) enhanced with intravascular gamma brachytherapy (IVBT) in
patients with renovascular hypertension.
Methods: Seventy one patients aged 52 ± 8 years with refractory renovascular hypertension
were randomized to Group I (PTRA + IVBT) or Group II (PTRA). For the IVBT procedure,
the PARIS catheter and Microselectron HDR (Nucletron) system was employed. Both baseline
and 9-month follow-up quantitative computerized angiography (QCA) and ambulatory blood
pressure monitoring analysis was performed to assess luminal parameters of restenosis and
the effect of treatment on blood pressure.
Results: Thirty three patients from Group I and 29 patients from Group II underwent successful
procedure. During nine months of follow-up, three patients died; including two patients in Group I
(cardiac causes) and one patient in Group II (stroke). The follow-up lumen diameter stenosis
was 30.6 ± 13.7% and 40.4 ± 11% in Groups I and II, respectively (p = 0.004). Late lumen
loss in quantitative computerized angiography was 1.2 ± 0.7 mm and 1.7 ± 0.7 mm in Groups I
and II, respectively (p = 0.004).
Conclusions: Intravascular gamma brachytherapy using self-centering source performed
after balloon angioplasty is a safe and effective method of prevention of restenosis after PTRA
in patients with renovascular hypertension. (Cardiol J 2009; 16, 6: 514–520)
Key words: brachytherapy, renal artery stenosis, atherosclerosis, percutaneous
transluminal renal angioplasty, hypertension
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Introduction
Among patients with potentially curable hyper-
tension, the most common secondary cause of high
blood pressure is renovascular hypertension due
to renal artery stenosis, mostly of atherosclerotic
origin [1–3]. Current data suggest that patients
with renovascular hypertension of atherosclerot-
ic origin may benefit from percutaneous revascu-
larization, and the clinical benefits include blood
pressure normalization or better blood pressure
control, improved or stable renal function, and
decreased requirement for antihypertensive drugs.
Despite proven efficacy of angioplasty, especially
with stent implantation, restenosis with its seque-
lae including worsening of blood pressure remains
a significant problem, prompting attempts to de-
crease this risk. New methods of preventing rest-
enosis that are currently under clinical investiga-
tion include drug-eluting stents and intravascular
brachytherapy [4].
The aim of this study was to examine the ef-
fect of brachytherapy on limiting restenosis and
blood pressure normalization as evaluated using
ambulatory blood pressure monitoring (ABPM)
during early and long-term follow-up after percuta-
neous transluminal renal angioplasty (PTRA) [5].
Methods
The study group included 71 consecutive pa-
tients aged more than 40 years with atherosclerot-
ic renal artery stenosis accompanied by drug-resist-
ant hypertension. The exclusion criteria included
bleeding diathesis, thrombocytopenia, contrast
agent intolerance, contraindications for the use of
heparin, aspirin or clopidogrel, reference artery
diameter of £ 3.0 mm, and stenosis localization un-
suitable for PTRA. The study protocol was approved
by a local Ethics Committee.
The diagnosis of renovascular hypertension of
atherosclerotic origin was established or confirmed
during hospitalization in the Department of Neph-
rology, Endocrinology and Metabolic Diseases, Si-
lesian Medical University. PTRA procedures were
performed in the Cardiac Catheterization Labora-
tory of the Silesian Center for Heart Disease, and
intravascular gamma brachytherapy was performed
in the Department of Brachyterapy, Maria Curie-
-Skłodowska Center of Oncology, Gliwice Branch, us-
ing PARIS® Catheter System self-centering sources.
The degree of renal artery stenosis was as-
sessed using quantitative computerized angiogra-
phy (QCA). Patients fulfilling the angiographic in-
clusion criteria were randomized to one of the two
groups using closed numbered envelopes (Fig. 1).
Two days prior to the PTRA procedure, pa-
tients were given 150 mg of acetylsalicylic acid and
300 mg of clopidogrel orally, and immediately be-
fore angioplasty 10,000 IU of heparin was adminis-
tered intravenously. Previous antiplatelet therapy
was also continued. According to the study proto-
col, a follow-up hospitalization at nine months was
planned to perform a follow up renal angiography,




PTRA was considered successful if the resid-
ual lumen stenosis was less than 30%, partially suc-
cessful if the residual lumen stenosis was 30–50%
with its decrease by at least 15% compared to the
baseline, and unsuccessful if the residual lumen
stenosis was more than 50%, or its decrease com-
pared to the baseline was less than 15%. During
long-term follow-up, PTRA was considered suc-
cessful if not accompanied by significant resteno-
sis, with the latter defined as recurrent lumen ste-
nosis of ≥ 50% at the site of the previously treated
lesion.
Invasive treatment efficacy based
on the effect on blood pressure
Considering blood pressure values as the effi-
cacy parameter [6, 7], the invasive treatment was
considered:
Figure 1. Study flowchart.
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— successful if postprocedural diastolic blood
pressure was less than 90 mm Hg and/or de-
creased by at least 10 mm Hg;
— partially successful (associated with some im-
provement of blood pressure control) if post-
procedural diastolic blood pressure was 90–
–110 mm Hg and decreased by at least 15%
compared to the preprocedural blood pressure
values;
— unsuccessful if postprocedural diastolic blood
pressure exceeded 110 mm Hg and decreased
by less than 15% compared to the preprocedu-
ral blood pressure values.
Angiography
Renal angiography and angioplasty was per-
formed by femoral or radial approach, using 6 F to
8 F sheaths, wires and catheters. Measurements of
renal arteries using QCA were performed on-line
during the invasive procedures, and included pre-
procedural, postoprocedural, and follow-up meas-
urements. Both procedural and follow-up QCA
measurements were also evaluated off-line by two
blinded experienced invasive cardiologists.
Blood pressure evaluation
Blood pressure was measured by 24-hour
ABPM before the procedure, at 48 hours after the
procedure, and during long-term follow-up. Elevat-
ed blood pressure values were defined as systolic
blood pressure above 140 mm Hg and diastolic blood
pressure above 90 mm Hg during the daytime
(6 am to 10 pm), and above 120 and 80 mm Hg, re-
spectively, during the nighttime. Automatic blood
pressure measurements were taken at 30 minutes
intervals.
Intravascular brachytherapy
Intravascular brachytherapy was performed
using the microSelectron HDR system (Nucletron)
with iridium-192 source mounted on a self-center-
ing PARIS catheter. Initial activity of the iridium-192
source was about 10 Ci. Reference isodose was
15 Gy at 2 mm from the surface of the centering
balloon. Average duration of irradiation was 3 min-
utes (range 1.5 to 4.5 min). Average time interval
between angioplasty and brachytherapy was
26 minutes. This delay, resulting from the need for
patient transfer from the catheterization laborato-
ry to the facility were gamma irradiation was per-
formed, was minimized by establishing a special
patient transfer system including dedicated ambu-
lance.
Statistical analysis
Normally distributed parameters were pre-
sented as means ± SD, and the differences be-
tween mean values were evaluated using the Stu-
dent t test. Non-normally distributed variables
were evaluated using the Mann-Whitney U test.
Categorical parameters were evaluated using the
c2 test with the Yates correction for expected size
of less than 5. P < 0.05 was considered statistical-
ly significant. All statistical analyses were per-
formed using the Statistica PL software, version 5.5
(StatSoft Inc.).
Results
The baseline clinical characteristics was simi-
lar in both groups. Overall, 71 patients (43 men and
28 women) were randomized and underwent PTRA
which was successful in 62 (87.3%) patients. In the
remaining nine (12.7%) patients (males only),
stents were implanted due to vessel dissection or
only partial balloon dilatation of the lesion and these
patients were excluded from the study as per pro-
tocol. No differences were found between baseline
renal angiographic parameters in 33 patients rando-
mized to PTRA and brachytherapy (Group I) and
29 patients randomized to PTRA only (Group II),
in whom PTRA was considered successful. No sig-
nificant differences were seen in renal angiograph-
ic parameters between Groups I and II immediate-
ly following PTRA. In contrast, long-term follow-
up showed that the treatment was more effective
in the brachytherapy group, as the late lumen loss
in QCA was 1.16 ± 0.73 mm in Group I versus 1.71 ±
± 0.67 in Group II (p = 0.0037). Restenosis rate
during long-term follow-up was 15.1% and 32.1%
in Groups I and II, respectively (p = 0.20).
Blood pressure before and
after the procedure
The mean 24-hour blood pressure before and
after PTRA was similar and did not differ signifi-
cantly between the two groups (Table 1). In both
groups, a significant decrease in systolic and diasto-
lic blood pressure and blood pressure load was seen
following the angioplasty (Table 1). Blood pressure
normalization without the need for antihypertensive
drug use was obtained in two (6%) patients in Group I
and two (6.9%) patients in Group II. The propor-
tion of patients with blood pressure lowering fol-
lowing the procedure was similar in both groups
(21 [63.6%] patients in Group I vs. 19 [65.5%] patients
in Group II). The treatment was unsuccessful in
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regard to blood pressure lowering in ten (30.3%)




Three patients died during the follow-up, in-
cluding 2/33 (6.1%) patients in Group I and 1/29
(3.4%) patients in Group II. The follow-up testing
as per protocol was performed in the remaining
31 patients in Group I and 28 patients in Group II.
During the long-term follow-up, normal blood pres-
sure without the use of antihypertensive drugs was
noted in 4/59 (6.8%) patients (two patients in each
group). During this period, i.e. between PTRA and
the follow-up testing, a significant increase in systo-
lic and diastolic blood pressure was observed in both
groups (Table 1). Systolic blood pressure values did
not differ significantly between the two groups
(p = 0.17), whereas diastolic blood pressure at the
end of follow-up was significantly more reduced in
Group I compared to Group II (15 ± 5 mm Hg vs.
13 ± 6 mm Hg; p = 0.05). In Group I, proportion of
elevated blood pressure values after the procedure
and at the final assessment was 70 ± 14% and
71 ± 15%, respectively (p = 0.56), for the systolic
pressure, and 65 ± 16% and 65 ± 17%, respectively
(p = 0.33), for the diastolic pressure. In contrast,
proportion of elevated blood pressure values in-
creased in Group II during the long-term follow-up
both for the systolic pressure (68 ± 20% after the
procedure vs. 78 ± 18% at the final assessment
p £ 0.001) and the diastolic pressure (64 ± 16% vs.
77 ± 18%, respectively, p £ 0.001). Overall, dura-
ble beneficial effect of the procedure in respect to
blood pressure lowering was seen during the long-
-term follow-up in 17/31 (54.8%) patients in Group I
and 10/28 (35.7%) patients in Group II.
At the final assessment, blood pressure re-
sponse was successful or partially successful in
19/31 (61.3%) patients in Group I and in 12/28
(42.8%) patients in Group II. Invasive treatment
was unsuccessful in 12 (38.7%) patients in Group I
and in 16/28 (57.2%) patients in Group II. The latter
patients required an increase in both number and dos-
es of the antihypertensive drugs (Table 2). No asso-
ciation was seen between the degree of renal artery
stenosis and blood pressure during the long-term fol-
low-up, although a trend was noted (p = 0.06). In
the present study, patients in both groups with
improved blood pressure control had shorter dura-
tion of hypertension and were younger than patients
with no improvement in blood pressure control
(Table 3). In Group I, no significant difference was
seen between the age of patients with improved
blood pressure control and patients with no im-
provement in blood pressure control (p = 0.2), while
duration of hypertension was significantly shorter in
patients with improved blood pressure control com-
pared to patients with no improvement in blood pres-
sure control (p = 0.05). Both these differences were
significant in Group II (p = 0.008 and p = 0.02, re-
spectively), with patients with no improvement in
blood pressure control being older and having long-
er duration of hypertension compared to patients
with improved blood pressure control.
Discussion
Primary treatment goals in patients with ren-
ovascular hypertension include normalization or
improved control of blood pressure, and improved
Table 1. Blood pressure before and after the invasive treament and at long-term follow-up.
Before invasive P After invasive P              Long-term P
treatment  treatment             follow-up
PTRA + BR PTRA PTRA + BR PTRA PTRA + BR PTRA
Mean SBP 152 ± 7 152 ± 8 0.98 144 ± 8 143 ± 8 0.93 145 ± 8 148±8 0.17
Proportion of
elevated values 89 ± 10 89 ± 10 1.0 70 ± 14 68 ± 20 0.65 71 ± 15 78±18 0.12
Mean DBP 108 ± 4 108 ± 5 0.76 91 ± 3 91 ± 4 0.48 93 ± 3 95 ± 5 0.05
Proportion of 96,6 ± 6 94 ± 9 0.37 65 ± 16 64 ± 16 0.76 65 ± 17 77±18 0.01
elevated values
Decrease in DBP* 17 ± 5 17.5 ± 5 0.84 15 ± 5 13 ± 6 0.05
Relative decrease 15 ± 4 16.5 ± 5 0.61 14 ± 4 12 ± 5 0.05
in DBP (%)
PTRA — percutaneous transluminal renal angioplasty; BR — brachytherapy; SBP — systolic blood pressure; DBP — diastolic blood pressure;
*postprocedural and long-term follow-up vs. baseline
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function of the ischemic kidney [8]. It should be
noted, however, that not every successful renal
angioplasty leads to normalization of blood pres-
sure, and in some patients renal artery stenosis is
not the major cause of hypertension. Published data
differ widely in regard to the effect of renal angi-
oplasty on blood pressure reduction and other clin-
ical outcomes in patients with atherosclerotic re-
nal artery stenosis [9–11]. In 1990 Ramsey et al.
[7] performed a metaanalysis of 10 nonrandomized
studies that showed limited efficacy of PTRA in the
treatment of atherosclerotic renal artery stenosis,
with outcomes similar to those in medically treat-
ed patients, and the proportion of patients with
blood pressure normalization not exceeding 8%.
Ascertainment of the real treatment effects is, how-
ever, difficult due to different patient selection cri-
teria, various methods used to measure blood pres-
sure, and varying criteria of improvement and cure.
Among 190 patients with atherosclerotic renal ar-
tery stenosis, including 99 men and 91 women, who
were treated by Bonelli et al. [12], successful blood
pressure lowering defined as systolic blood pres-
sure £ 140 mm Hg and diastolic blood pressure
£ 90 mm Hg without the use of antihypertensive
drugs was noted in only 8.4% of patients. The mean
age in this patient subset, 58.6 years, was lower than
among 70% of patients with only partial blood pres-
sure response (64.8 years; p = 0.05). The authors
noted that blood pressure normalization following
successful angioplasty in all patients with athero-
sclerotic renal artery stenosis is unlikely as coex-
isting essential hypertension might be present in
most of these patients. Van Jaarsveld et al. [13]
compared PTRA and medical treatment of renovas-
cular hypertension in a randomized study in 106 pa-
tients. No significant differences of systolic and
diastolic blood pressure were noted between the
two groups at 3 months of follow-up. However, at
12 months blood pressure normalization without the
use of antihypertensive drugs was seen in 7% (4/56)
of patients compared to none of the patients in the
medical treatment group, and improved blood pres-
sure control in 68% (38/56) of patients compared
to 38% (18/48) of patients treated medically. The
choice of the invasive approach was also supported
by the fact that 50% of patients in the medical treat-
ment group were eventually treated with angio-
plasty due to inadequate blood pressure control
and worsening of renal function. In a metaanalysis
by Leertouwer et al. [14] in patient with atheroscle-
rotic renal artery stenosis, blood pressure normal-
ization without the use of antihypertensive drugs
was noted in 10% (54/544) of patients undergoing
PTRA, and somewhat lower proportion of patients
cured by PTRA (8%) was reported by Klow et al.
[15]. Better outcomes may be obtained by combin-
ing angioplasty with stenting, as blood pressure nor-
malization without the use of antihypertensive drugs
was noted in 11% (38/334) of such patients [8, 14].
Table 3. Duration of the disease and age in relation to improvement of blood pressure control in
the study groups.
                                         PTRA + brachytherapy PTRA
Improvement No improvement P Improvement No improvement P
Age 49.9 ± 6.6 54.1 ± 8.7 0.2 48.2 ± 6.4 55.9 ± 7.8 0.008
Disease duration 6.4 ± 3.2 9.6 ± 4.5 0.05 5.4 ± 3.3 8.5 ± 2.9 0.02
PTRA — percutaneous transluminal renal angioplasty
Table 2. Total daily dose of all antihypertensive drugs used before and after the invasive treatment and
at long-term follow-up in the study groups (with a full dose of one drug counted as 1).
Before After Long-term P P P
follow-up 1 vs. 2 2 vs. 3 1 vs. 3
1 2 3
Dose (PTRA + brachytherapy) 3.2 ± 0.9 1.9 ± 1.1 2.1 ± 1.0 < 0.001 < 0.001 < 0.001
Dose (PTRA) 3.3 ± 0.9 2.0 ± 0.8 2.8 ± 1.3 < 0.001 < 0.001 0.050
P (PTRA + brachytherapy vs. PTRA) 0.63 0.66 0.038
PTRA — percutaneous transluminal renal angioplasty
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Taking into account various criteria used in
different studies, it has been estimated that in many
centers the proportion of patients with blood pres-
sure normalization without the use of antihyperten-
sive drugs following PTRA ranges from 8 to 11%
[7, 16]. The role of angioplasty compared to medi-
cal treatment in patient with renal artery stenosis
has been further clarified by a metaanalysis of
DRASTIC, SNRASCG, and EMMA studies [11, 17,
18] that was performed by Nordmann et al. [19].
These three studies included 210 patients with re-
nal artery stenosis of ≥ 50% and difficult-to-con-
trol hypertension. Overall, angioplasty without
stenting was associated with reduced requirement
for antihypertensive drugs and better blood pres-
sure control (on average by 7/3 mm Hg compared
to medical treatment), but the effect on renal func-
tion was comparable [11, 17, 18].
Our study showed that renal angioplasty com-
bined with brachytherapy reduces the risk of rest-
enosis during a 9-month follow-up by about 50%
compared to balloon angioplasty only (32.1% vs.
16.1%). Our criteria of successful treatment in re-
gard to blood pressure control were quite stringent,
resulting in low proportion of hypertension cure at
long-term follow-up (4/59 patients, i.e. 7%). Im-
provement of blood pressure control was seen in
54.8% of patients in the brachytherapy group and
35.7% of patients in the PTRA group. Most studies
reported more beneficial effect of PTRA on blood
pressure control and renal function compared to
medical treatment. This was also reflected by a re-
duced number of antihypertensive drugs used af-
ter the invasive treatment [7]. Our findings regard-
ing the number and doses of antihypertensive drugs
in relation to blood pressure control before and af-
ter the invasive treatment and at long-term follow-
up are fully concordant with the previous results.
Our findings showing a difference between the
groups in the number of antihypertensive drugs
used suggest that brachytherapy has a positive ef-
fect of renal artery patency and contributes to bet-
ter blood pressure control during the long-term fol-
low-up compared to angioplasty only. In addition,
long-standing renal artery stenosis that is treated
medically may lead to irreversible vascular struc-
tural changes, with increased stiffness of the ves-
sel wall, as well as functional changes related to
endothelial dysfunction. If these changes persist for
a long time, even correction of the lesion by angi-
oplasty, angioplasty with stenting, or angioplasty
with brachytherapy, as in the present study, may
not lead to durable normalization of blood pressure
and renal function despite reversal of normal flow
in the renal artery [20]. Thus, blood pressure nor-
malization following angioplasty is more likely in
younger patients with shorter disease duration and
a smaller likelihood of sustained changes in renal
microcirculation [7, 16, 18, 20]. Our findings seem
to support this view, alhough in our study age cor-
related with improvement in blood pressure param-
eters only in those patients who were not treated
with brachytherapy (p = 0.008). In addition, in both
groups duration of the disease was shorter in pa-
tients with improved blood pressure control follow-
ing the invasive treatment.
In summary, the effectiveness of angioplasty
in a broad population of patients with renal artery
stenosis remains controversial. The key issue
seems to be proper selection of patients who are
most likely to benefit from the invasive treatment.
This highlights the importance of appriopriate dia-
gnostic work-up and evaluation whether in a par-
ticular case medical treatment only is sufficient or
should be supplanted by angioplasty [15]. Treat-
ment decisions should be made on an individual
basis, taking into account the previous course of the
disease and the patient condition. It seems that
medical treatment might be preferred over the in-
vasive approach in the elderly patients who are both
less likely to benefit from the intervention and are
at higher risk of procedure-related complications.
Our findings in regard to blood pressure con-
trol support a significant effect of brachytherapy on
the long-term efficacy of the invasive treament of
atherosclerotic renal artery stenosis. It remains,
however, debatable, whether renal angioplasty
should be considered as a treatment option in all
patients with atherosclerotic renal artery stenosis.
Cleary, screening all patients with hypertension for
atherosclerotic renal artery stenosis with a prospect
of angioplasty is not justified. On the other hand,
renal angioplasty may be indicated in patients with
atherosclerotic renal artery stenosis in whom blood
pressure control remains inadequate despite the
use of optimal antihypertensive drug regimen.
Conclusions
1. Complete blood pressure normalization with-
out the use of antihypertensive drugs is a rare
occurrence in patients with atherosclerotic re-
nal artery stenosis despite successful angiopla-
sty, but improved blood pressure control may
be noted in many of these patients.
2. Angioplasty of renal artery stenosis leads to
a decrease in systolic and diastolic blood pres-
sure during hospital stay, but some subsequent
520
Cardiology Journal 2009, Vol. 16, No. 6
www.cardiologyjournal.org
increase in blood pressure may be noted du-
ring long-term follow-up.
3. In patients undergoing brachytherapy, increase
in diastolic blood pressure during long-term
follow-up was significantly lower compared to
patients who were treated only with PTRA.
4. Improved vessel patency resulting from the
use of brachytherapy attenuates the negative
effect of longer duration of hypertension on im-
provement of blood pressure control during
long-term follow-up.
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